BIOS Capital Management LP Invests $3.85 Million in Lantern Pharma Inc. (NASDAQ:LTRN)

BIOS Capital Management LP bought a new position in Lantern Pharma Inc. (NASDAQ:LTRN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,207,709 shares of the company’s stock, valued at approximately $3,853,000. Lantern Pharma makes up approximately 4.1% of BIOS Capital Management LP’s portfolio, making the stock its 4th largest holding. BIOS Capital Management LP owned 11.20% of Lantern Pharma as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sanctuary Advisors LLC bought a new position in shares of Lantern Pharma in the 4th quarter worth approximately $32,000. Westside Investment Management Inc. raised its position in shares of Lantern Pharma by 166.5% in the 3rd quarter. Westside Investment Management Inc. now owns 30,650 shares of the company’s stock worth $112,000 after acquiring an additional 19,150 shares in the last quarter. Finally, CM Management LLC raised its position in shares of Lantern Pharma by 8.1% in the 4th quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $638,000 after acquiring an additional 15,000 shares in the last quarter. Institutional investors own 28.62% of the company’s stock.

Lantern Pharma Stock Performance

Shares of NASDAQ:LTRN opened at $3.80 on Monday. Lantern Pharma Inc. has a 52-week low of $2.79 and a 52-week high of $11.99. The firm has a market capitalization of $40.98 million, a P/E ratio of -2.13 and a beta of 1.64. The stock has a 50 day moving average price of $4.27 and a 200-day moving average price of $3.78.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.